Cardinal Health Reaffirms Fiscal 2024 non-GAAP EPS Guidance and Long-term Targets Amidst Nonrenewal of OptumRx Customer Contracts

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. SPY
4. MU
5. META
6. FDX
7. IBM
8. PRIM
9. ACN
10. USO

Go back to Cardinal Health Reaffirms Fiscal 2024 non-GAAP EPS Guidance and Long-term Targets Amidst Nonrenewal of OptumRx Customer Contracts

Baird Defends Cardinal Health (CAH): 'Market fears played out, buyers on weakness'

April 23, 2024 6:21 AM EDT

Baird analyst Eric Coldwell reiterated an Outperform rating and $134.00 price target on Cardinal Health (NYSE: CAH).

The analyst comments "Market fears played out, buyers on weakness. We have long posited that CAH could well absorb loss of OptumRx given strong underlying market fundamentals,... More